Table 6.
Predictive factors for complete pathological response in univariate logistic regression analysis for the capecitabine/deGramont-RT regimen
| Variable | Non-pCR (n = 102) n P50 (P25-P75) | pCR (n = 13) n P50 (P25-P75) | pCR rate | P-value | |
| Gender | Male | 70 | 6 | 7.89% | 0.096 |
| Female | 31 | 7 | 18.42% | ||
| Age (yr) | ≤ 60 | 56 | 10 | 15.15% | 0.131 |
| > 60 | 46 | 3 | 6.12% | ||
| BMI (kg/cm2) | < 25 | 75 | 8 | 9.64% | 0.375 |
| ≥ 25 | 21 | 4 | 16.00% | ||
| Hemoglobin (g/L) | ≤ 125 | 33 | 1 | 2.94% | 0.087 |
| > 125 | 56 | 9 | 13.85% | ||
| NLR | > 3 | 12 | 4 | 25.00% | 0.031 |
| ≤ 3 | 77 | 6 | 7.23% | ||
| PLT (×109/L) | 228 (188.25-266.75) | 252 (188.75-319) | 0.338 | ||
| ApoA1 (g/L) | 1.3 (1.14-1.48) | 1.34 (1.11-1.46) | 0.912 | ||
| ApoB (g/L) | 0.97 (0.8-1.09) | 0.92 (0.78-1.02) | 0.667 | ||
| The interval | 53.97 ± 8.94 | 52.38 ± 10.79 | 0.588 | ||
| CEA (ng/mL) | > 5 | 51 | 5 | 8.93% | 0.659 |
| ≤ 5 | 38 | 5 | 11.63% | ||
| Differentiation | Moderate-poor | 82 | 8 | 8.89% | 0.177 |
| Well | 17 | 4 | 19.05% | ||
| DTAV (cm) | < 5 | 52 | 9 | 14.75% | 0.214 |
| ≥ 5 | 50 | 4 | 7.41% | ||
| TL (cm) | > 3 | 74 | 8 | 9.76% | 0.252 |
| ≤ 3 | 23 | 5 | 17.86% | ||
| TCE | ≤ 50% | 10 | 0 | 0.00% | 0.241 |
| > 50% | 79 | 11 | 12.22% | ||
| cT | 2 | 7 | 2 | 22.22% | 0.521 |
| 3 | 75 | 10 | 11.76% | ||
| 4 | 14 | 1 | 6.67% | ||
| cN | + | 73 | 11 | 13.10% | 0.394 |
| - | 26 | 2 | 7.14% | ||
| MRF | - | 74 | 11 | 12.94% | 0.377 |
| + | 27 | 2 | 6.90% | ||
Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.